Ownership and insider activity for Rhythm Pharmaceuticals, Inc. (RYTM): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
Price
| Price | $86.44 (closing price, November 3, 2026) |
| Market Cap | $6.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-14 | Meeker David P | M-Exempt | 50,000 | $302K |
| 2026-09-14 | Meeker David P | S-Sale | 6,439 | $655K |
| 2026-09-14 | Meeker David P | S-Sale | 30,746 | $3.1M |
| 2026-09-14 | Meeker David P | S-Sale | 8,698 | $900K |
| 2026-09-14 | Meeker David P | S-Sale | 1,817 | $190K |
| 2026-09-14 | Meeker David P | S-Sale | 2,300 | $242K |
| 2026-09-14 | Meeker David P | M-Exempt | 50,000 | $302K |
| 2026-08-31 | Smith Hunter C | M-Exempt | 57,187 | $1.5M |
| 2026-08-31 | Smith Hunter C | S-Sale | 23,072 | $2.4M |
| 2026-08-31 | Smith Hunter C | S-Sale | 11,514 | $1.2M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.5M | $34.2M | $49.5M | $62.3M | $100.9M | $59.2M | $127.7M | $60.1M | $89.1M | $54.3M |
| Short-term Investments | $4.0M | $113.8M | $202.5M | $230.2M | $71.9M | $235.6M | $205.6M | $215.8M | $231.4M | $334.6M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $1.0M | $6.2M | $14.9M | $18.5M | $26.1M |
| Inventory | 0 | 0 | 0 | 0 | 0 | $111,000 | $2.9M | $8.6M | $18.7M | $25.8M |
| Total Current Assets | $11.2M | $150.7M | $258.7M | $302.4M | $181.7M | $308.4M | $354.2M | $308.3M | $374.2M | $466.9M |
| Property, Plant & Equipment | $930,000 | $840,000 | $1.1M | $5.7M | $5.0M | $4.3M | $3.4M | $2.1M | $4.1M | $4.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $4.7M | $7.9M | $7.0M | $6.2M | $5.3M |
| Total Assets | $12.3M | $151.7M | $260.2M | $308.5M | $187.1M | $329.5M | $382.5M | $332.7M | $392.3M | $480.2M |
| Accounts Payable | $1.9M | $2.4M | $7.6M | $10.4M | $4.9M | $5.7M | $4.8M | $4.9M | $12.3M | $13.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.7M | $6.7M | $13.6M | $24.4M | $18.0M | $43.4M | $39.8M | $55.2M | $115.5M | $105.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $5.0M | $6.9M | $14.0M | $27.5M | $20.5M | $45.4M | $118.2M | $163.0M | $227.7M | $210.2M |
| Retained Earnings | -$76.5M | -$110.3M | -$184.6M | -$325.3M | -$459.3M | -$528.9M | -$710.1M | -$894.7M | -$1.16B | -$1.35B |
| Total Equity | $7.3M | $144.8M | $246.3M | $281.0M | $166.5M | $284.2M | $264.3M | $169.8M | $164.5M | $270.0M |
| Total Debt | 0 | 0 | 0 | $3.6M | $3.1M | $2.6M | $1.9M | $1.3M | $3.9M | $4.0M |
| Net Debt | -$10.5M | -$148.1M | -$252.1M | -$288.9M | -$169.7M | -$292.3M | -$331.3M | -$274.6M | -$316.6M | -$385.0M |
| Working Capital | $6.4M | $144.0M | $245.1M | $278.0M | $163.7M | $265.0M | $314.4M | $253.1M | $258.7M | $361.0M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 2.78 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 15.89 |
Profitability
| Return on Equity | -83.68% |
| Return on Invested Capital | -63.91% |
| Return on Assets | -43.74% |
| Gross Margin | 88.23% |
| Operating Margin | -66.70% |
| Net Margin | -69.03% |
Related companies: BMRN · BLTE · VKTX · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of RYTM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks